ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1133

Long-Term Renal Outcome and Mortality in Hospitalized Patients with COVID-19 Infection and AKI at UCLA

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Nobakht, Niloofar, University of California Los Angeles, Los Angeles, California, United States
  • Jang, Charley Qi Hua, University of California Los Angeles, Los Angeles, California, United States
  • Kamgar, Mohammad, University of California Los Angeles, Los Angeles, California, United States
Background

Acute kidney injury (AKI) is a common complication in patients with COVID-19 infection and has been associated with poor outcomes. At the ASN 2022 Kidney Week, we presented data from RECOVID study evaluating the need for renal replacement therapy (RRT) and early mortality among patients with COVID-19 infection and AKI in both vaccinated and unvaccinated populations. Here we present updated long term mortality follow-up data from RECOVID cohort.

Methods

In this retrospective, observational cohort study, we explored long term mortality data for the RECOVID cohort, which evaluated patients admitted for COVID-19 infection who developed an AKI at UCLA from March 2020. These patients were followed until February 2023.

Results

Among the 3527 hospitalized patients with COVID-19, 878 patients met criteria for inclusion in the study. Of the 878 patients with AKI 46.8% did not receive the COVID-19 vaccine and 53.2% were vaccinated. When evaluating long term follow-up among AKI patients, vaccinated patients continued to have significantly less mortality with a mean survival of 715 days (95% CI, 667-762) as compared to unvaccinated patients with a mean survival of 316 days (95% CI, 262-369). Association of unvaccinated status with shorter overall survival remained significant after multivariate analysis (HR, 5.11 [3.87- 6.76]; P < .001).

Conclusion

Vaccinated patients with COVID-19 infection and AKI had improved long-term survival and were less likely to be dialysis-dependent.

Table 1. Patient Characteristics and Outcomes